LIVE NOW:Watch the Definedge Conference on Market Analysis (DECMA). Join Now
you are here: HomeNewsTrendsHealth

Pfizer wants to make vaccine in India if faster clearance, export freedom assured: Report

The US company pulled an application last month seeking emergency approval for its product in India after the drug regulator declined its request to skip a small local safety trial. That has kept its vaccine, developed with Germany's BioNTech SE, out of one of the world's biggest drug markets.

March 10, 2021 / 05:32 PM IST
Source: Reuters

Source: Reuters

Pfizer Inc has told the Indian government it wants to produce its coronavirus vaccine locally if assured of faster regulatory clearance and freedom on pricing and exports, two sources with direct knowledge of the matter told Reuters.

The US company pulled an application last month seeking emergency approval for its product in India after the drug regulator declined its request to skip a small local safety trial. That has kept its vaccine, developed with Germany's BioNTech SE, out of one of the world's biggest drug markets.

Pfizer was the first company to apply for emergency use authorisation in India, proposing to import doses from its US and European facilities instead of producing locally.

"US companies want to produce vaccines in India under joint ventures," said one of the sources, citing Pfizer and fellow US drugmaker Moderna Inc.

"They want faster approvals for clinical trials and emergency authorisation use. They fear the government will introduce price control policies."

Close

COVID-19 Vaccine

Frequently Asked Questions

View more
How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.

View more
Show

Another source confirmed Pfizer was interested in manufacturing in India but Reuters could not find a second confirmation on Moderna.

The companies did not immediately respond to requests for comment. India's health ministry directed Reuters to the foreign ministry, which did not immediately respond to emailed queries.

While withdrawing its application in early February, Pfizer said it would again seek emergency use approval to launch its COVID-19 vaccine in India, potentially a market of 1.35 billion people, and would provide more data as it becomes available.

On the government's demand to manufacture in India, the company earlier told Reuters: "Once the pandemic supply phase is over and we enter a phase of regular supplies, Pfizer will evaluate all additional opportunities available."

Follow our LIVE blog for latest updates of the novel coronavirus pandemic

A Indian official told Reuters in January the government had held discussions with Pfizer and Moderna - both of which have reported more than 90 percent efficacy for their vaccines - to make the shots in India given its large pharmaceuticals capacity.

The Serum Institute of India, the world's largest vaccine maker, is already bulk-manufacturing the Oxford University/AstraZeneca product and plans to start producing the Novavax Inc shot from next month.

India's government has not allowed it to sell on the higher-priced private market, however, and is also controlling exports. Pfizer and Moderna, whose shots are more expensive than the AstraZeneca one being used in India's immunisation campaign, are not comfortable with strict price and export restrictions, one of the sources said.

This week, Reuters reported that leaders of the Quad alliance - Australia, Japan, India and the United States - plan to announce financing agreements to increase India's vaccine manufacturing capacity at their first meeting on Friday.

The initiative will mainly involve production of the Novavax and Johnson & Johnson shots for supplying to regions including Southeast Asia, where their common rival China is making gains.

Follow our full coverage of the coronavirus pandemic here.
Reuters
first published: Mar 10, 2021 05:24 pm

stay updated

Get Daily News on your Browser
Sections